Allergan, Mohawk tribe ask SCOTUS to review Restasis deal by Arlene Weintraub Wednesday, January 16, 2019 Can tribal immunity shield a drug—in this case, Restasis—from a patent challenge? Allergan and the Mohawk tribe want the Supreme Court to weigh in.
Can Botox hang with CGRP in migraine? Allergan says yes by Carly Helfand Monday, January 14, 2019 Last week, Allergan's CEO told investors that Botox “continues to remain very strong” in migraine despite the arrival of three new CGRP drugs. But how strong?
Top pharma companies ring in 2019 with price hikes by Eric Sagonowsky Wednesday, January 2, 2019 After controversy and a price-hiking pause for some companies last year, several drugmakers are raising prices in early 2019.
Merz launches awareness and branded Xeomin efforts by Beth Snyder Bulik Monday, December 10, 2018 Merz Americas hopes to grab cosmetic injection share with two new ad campaigns that push awareness of options other than market leader Botox.
J&J CEO: Amazon could shake up rebates and more for pharma by Eric Sagonowsky Tuesday, December 11, 2018 J&J CEO Alex Gorsky said Amazon could offer expertise in distribution as well as shake up reimbursement in a potential pharma entry.
Teva hit with $6.3M retaliation verdict in ex-staffer's lawsuit by Eric Sagonowsky Monday, December 3, 2018 A judge ruled that Teva must face a lawsuit alleging employment discrimination in September, and now jurors ordered the company to pay $6.3 million.
Philadelphia looks to register pharma reps, ban gifts by Beth Snyder Bulik Thursday, November 29, 2018 Philadelphia's city council is considering legislation to regulate pharma reps including prohibiting any gifts to healthcare providers and staff.
Allergan taps 'Sex and the City' actress to talk 'denim denial' by Beth Snyder Bulik Sunday, November 18, 2018 Too-snug jeans in the back of the closet? Allergan’s newest spokescelebrity can relate, and she's talking about her CoolSculpting story.
AZ chief: Europe should pay more for drugs—and the U.S., less by Eric Sagonowsky Thursday, November 8, 2018 A top pharma CEO says President Trump is right to say other countries benefit from higher U.S. drug prices, but he’s not sold on proposals for a fix.
Allergan nixes Texas plant expansion as Restasis generics loom by Eric Palmer Monday, November 5, 2018 With generics expected soon for eye drug Restasis, Allergan has canceled a $200 million expansion at its Waco, Texas, manufacturing plant.
